GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Merck & Co. Shells Out $1.1B for Sirna

  • Merck & Co. will acquire Sirna Therapeutics for a cash value of approximately $1.1 billion. At $13 per share, this amount is more than double Sirna’s closing price of $6.45 on October 30, 2006. Sirna is currently trading at $12.7 per share.
    "This is another example of Merck delivering on its strategy of aggressively pursuing biotechnology companies that complement our considerable internal research capabilities," remarks Richard N. Kender, vp of business development and corporate licensing.

    Sirna creates RNAi-based therapeutics. Its lead clinical development candidate, Sirna-027, is a chemically optimized, siRNA currently moving into Phase II development for the treatment of the wet-form of age-related macular degeneration as part of a broad collaboration with Allergan. The company also has an alliance with GlaxoSmithKline for the development of siRNA compounds for the treatment of respiratory diseases. In addition, Sirna has several programs covering a range of therapeutic areas, including infectious diseases, metabolism, CNS, and dermatology.

    Merck and Sirna expect to complete the acquisition in the first quarter of 2007. Sirna stockholders who own approximately 36% of the company’s outstanding shares have said they will support the transaction and have entered into voting agreements.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?